The aim of the study is to evaluate melatonin effect on coagulation following hemorrhagic stroke. This survey is a randomized clinical trial on 30 patients in intensive care unit (Sina hospital). Patients who are eligible to be included in the trial, admission to ICU within 72 hours of hemorrhagic stroke, will be randomly enrolled in two groups after a written consent is obtained. Patients in the first group will be receiving 30 mg of Melatonin daily via gastric tube while patients in the second group will not receive this medicine. Patients in each group will receive the standard treatment for hemorrhagic stroke. Each patient will be monitored for 5 days and 2 blood samples will be taken, first before melatonin administration and then 5 days later. Blood samples will be centrifuged and the serum will be kept in -80 C for later assessments. Markers which will be evaluated include D-dimer, fibrinogen, platelet count, PT, PTT, TT, serum melatonin level, Tissue Factor (TF), Tissue Factor Pathway Inhibitor (TFPI), Von Willebrand Factor (vWF), Plasminogen Activator Inhibitor type 1 (PAI-1) and Factors VIIa, XIIa and XIIIa. Parameters of neurologic improvement will be monitored on daily basis.